Table of Content

Open AccessOpen Access


PDA: To treat or not to treat

Meera N. Sankar, Shazia Bhombal, William E. Benitz

Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Palo Alto, California

* Corresponding Author: William E. Benitz, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, 750 Welch Rd, Suite 315, Palo Alto, CA 94034, USA . Email:

Congenital Heart Disease 2019, 14(1), 46-51.


Management of patent ductus arteriosus in extremely preterm infants remains a topic of debate. Treatment to produce ductal closure was widely practiced until the past decade, despite lack of evidence that it decreases morbidities or mortality. Meta‐analyses of trials using nonsteroidal anti‐inflammatory drugs have shown ef‐ fectiveness in accelerating ductal closure, but no reduction in neonatal morbidities, regardless of agent used, indication, timing, gestational age, or route of administra‐ tion. Surgical ligation closes the ductus but is associated with adverse effects. Recent experience with conservative approaches to treatment suggest improved neonatal outcomes and a high rate of spontaneous ductal closure after discharge. Careful postdischarge follow‐up is important, however, because potential adverse effects of long‐standing aortopulmonary shunts may be an indication for catheter‐ based ductal closure. Identification of extremely preterm infants at greatest risk of potential harm from a persistently patent ductus, who may benefit most from treat‐ ment are urgently needed.


Cite This Article

Sankar, M. N., Bhombal, S., Benitz, W. E. (2019). PDA: To treat or not to treat. Congenital Heart Disease, 14(1), 46–51.

This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1332


  • 952


  • 0


Related articles

Share Link